Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN').

PubWeight™: 5.39‹?› | Rank: Top 1%

🔗 View Article (PMID 17352710)

Published in Am J Transplant on March 01, 2007

Authors

K Solez1, R B Colvin, L C Racusen, B Sis, P F Halloran, P E Birk, P M Campbell, M Cascalho, A B Collins, A J Demetris, C B Drachenberg, I W Gibson, P C Grimm, M Haas, E Lerut, H Liapis, R B Mannon, P B Marcus, M Mengel, M J Mihatsch, B J Nankivell, V Nickeleit, J C Papadimitriou, J L Platt, P Randhawa, I Roberts, L Salinas-Madriga, D R Salomon, D Seron, M Sheaff, J J Weening

Author Affiliations

1: University of Alberta, Edmonton, Alberta, Canada. Kim.Solez@ualberta.ca

Associated clinical trials:

Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection | NCT01134510

A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients | NCT01163799

Articles citing this

(truncated to the top 100)

Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A (2007) 2.27

Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol (2012) 2.16

The Kidney Donor Profile Index (KDPI) of marginal donors allocated by standardized pretransplant donor biopsy assessment: distribution and association with graft outcomes. Am J Transplant (2014) 1.80

The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol (2012) 1.71

Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med (2013) 1.68

Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol (2008) 1.62

Clinical role of the renal transplant biopsy. Nat Rev Nephrol (2012) 1.46

Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens (2012) 1.46

Vienna experience of ABO-incompatible living-donor kidney transplantation. Wien Klin Wochenschr (2009) 1.42

Transcriptional Perturbations in Graft Rejection. Transplantation (2015) 1.40

Urinary expression of kidney injury markers in renal transplant recipients. Clin J Am Soc Nephrol (2010) 1.32

Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol (2008) 1.29

Differentially expressed RNA from public microarray data identifies serum protein biomarkers for cross-organ transplant rejection and other conditions. PLoS Comput Biol (2010) 1.27

Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant (2010) 1.23

Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol Cell Proteomics (2009) 1.18

Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol (2009) 1.16

Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol (2008) 1.15

Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study. Am J Transplant (2010) 1.14

Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies. J Am Soc Nephrol (2010) 1.13

Acoustic radiation force impulse imaging for noninvasive evaluation of renal parenchyma elasticity: preliminary findings. PLoS One (2013) 1.13

Nox-2 is a modulator of fibrogenesis in kidney allografts. Am J Transplant (2008) 1.11

Late kidney allograft loss: what we know about it, and what we can do about it. Clin J Am Soc Nephrol (2008) 1.11

Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses. Transplantation (2010) 1.10

Accommodation in organ transplantation. Curr Opin Organ Transplant (2008) 1.08

The evolution of the Banff classification schema for diagnosing renal allograft rejection and its implications for clinicians. Indian J Nephrol (2010) 1.05

Regulatory, effector, and cytotoxic T cell profiles in long-term kidney transplant patients. J Am Soc Nephrol (2009) 1.05

Minimally invasive robotic kidney transplantation for obese patients previously denied access to transplantation. Am J Transplant (2013) 1.04

Accommodation of grafts: implications for health and disease. Hum Immunol (2007) 1.04

Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol (2008) 1.04

Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS One (2009) 1.03

Tribbles-1 as a novel biomarker of chronic antibody-mediated rejection. J Am Soc Nephrol (2008) 1.03

Renal allograft pathology with C4d immunostaining in patients with graft dysfunction. Indian J Nephrol (2011) 1.02

Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol (2008) 1.02

Recent developments in kidney transplantation--a critical assessment. Am J Transplant (2009) 1.02

The two kidney to one kidney transition and transplant glomerulopathy: a podocyte perspective. J Am Soc Nephrol (2014) 1.01

Mechanism of cellular rejection in transplantation. Pediatr Nephrol (2010) 1.01

Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. J Am Soc Nephrol (2015) 1.00

MR elastography in renal transplant patients and correlation with renal allograft biopsy: a feasibility study. Acad Radiol (2012) 0.99

Vitamin D status and outcomes after renal transplantation. J Am Soc Nephrol (2013) 0.97

Randomized trial of immunosuppressive regimens in renal transplantation. J Am Soc Nephrol (2011) 0.97

Preserving the B-cell compartment favors operational tolerance in human renal transplantation. Mol Med (2012) 0.97

A Three-Gene Assay for Monitoring Immune Quiescence in Kidney Transplantation. J Am Soc Nephrol (2014) 0.96

Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits. Am J Transplant (2009) 0.96

Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients. J Am Soc Nephrol (2014) 0.96

Differential expression of proteoglycans in tissue remodeling and lymphangiogenesis after experimental renal transplantation in rats. PLoS One (2010) 0.95

Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol (2010) 0.94

Molecular pathways involved in loss of kidney graft function with tubular atrophy and interstitial fibrosis. Mol Med (2008) 0.94

Alternatively activated macrophages in the pathogenesis of chronic kidney allograft injury. Pediatr Nephrol (2014) 0.94

A rapid noninvasive assay for the detection of renal transplant injury. Transplantation (2013) 0.93

Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathway. Transplantation (2010) 0.93

Epithelial-to-mesenchymal transition in early transplant tubulointerstitial damage. J Am Soc Nephrol (2008) 0.93

Integrative analysis of -omics data and histologic scoring in renal disease and transplantation: renal histogenomics. Semin Nephrol (2010) 0.91

Renal transplant rejection markers. World J Urol (2007) 0.91

What is the best way to measure renal fibrosis?: A pathologist's perspective. Kidney Int Suppl (2011) (2014) 0.90

Role of complement and NK cells in antibody mediated rejection. Hum Immunol (2012) 0.89

Endothelial cell antibodies associated with novel targets and increased rejection. J Am Soc Nephrol (2014) 0.89

Pathologic characteristics of transplanted kidney xenografts. J Am Soc Nephrol (2011) 0.89

The identification of novel potential injury mechanisms and candidate biomarkers in renal allograft rejection by quantitative proteomics. Mol Cell Proteomics (2013) 0.89

Diagnostic challenges in chronic antibody-mediated rejection. Nat Rev Nephrol (2012) 0.88

Clinical significance of the ratio between FOXP3 positive regulatory T cell and interleukin-17 secreting cell in renal allograft biopsies with acute T-cell-mediated rejection. Immunology (2012) 0.88

Deceased donor organ transplantation: A single center experience. Indian J Nephrol (2011) 0.88

Chronic alloantibody mediated rejection. Semin Immunol (2011) 0.87

Monocytes/macrophages in kidney allograft intimal arteritis: no association with markers of humoral rejection or with inferior outcome. Nephrol Dial Transplant (2009) 0.87

An experimental model of acute humoral rejection of renal allografts associated with concomitant cellular rejection. Am J Pathol (2008) 0.87

Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol (2010) 0.86

Molecular phenotypes of acute rejection predict kidney graft prognosis. J Am Soc Nephrol (2009) 0.85

Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques. Am J Transplant (2012) 0.85

Perturbations in the urinary exosome in transplant rejection. Front Med (Lausanne) (2015) 0.85

Chronic allograft nephropathy. Pediatr Nephrol (2008) 0.85

Diagnostic significance of peritubular capillary basement membrane multilaminations in kidney allografts: old concepts revisited. Transplantation (2012) 0.85

Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol (2016) 0.85

Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. Transpl Immunol (2012) 0.84

Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus. Kidney Int (2014) 0.84

Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. Methods Mol Biol (2013) 0.84

Anti-huCD20 antibody therapy for antibody-mediated rejection of renal allografts in a mouse model. Am J Transplant (2015) 0.84

The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol (2010) 0.84

Transplant glomerulopathy: the interaction of HLA antibodies and endothelium. J Immunol Res (2014) 0.84

Low-dose carbon monoxide inhibits progressive chronic allograft nephropathy and restores renal allograft function. Am J Physiol Renal Physiol (2009) 0.83

A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. Transplantation (2015) 0.83

Recent advances in renal transplantation: antibody-mediated rejection takes center stage. F1000Prime Rep (2015) 0.83

The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss. Kidney Int (2015) 0.83

CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients. Eur J Clin Pharmacol (2009) 0.82

Long-term impact of pretransplant and posttransplant diabetes mellitus on kidney transplant outcomes. World J Surg (2011) 0.82

Higher infiltration by Th17 cells compared with regulatory T cells is associated with severe acute T-cell-mediated graft rejection. Exp Mol Med (2011) 0.82

Prevalence and risk factors for early chronic allograft nephropathy in a live related renal transplant program. J Nephropathol (2014) 0.82

Intragraft levels of Foxp3 mRNA predict progression in renal transplants with borderline change. J Am Soc Nephrol (2008) 0.82

Intragraft expression of the IL-10 gene is up-regulated in renal protocol biopsies with early interstitial fibrosis, tubular atrophy, and subclinical rejection. Am J Pathol (2010) 0.82

Journal of Nephropathology: A need of the hour. J Nephropathol (2012) 0.82

The imbalance between Tregs, Th17 cells and inflammatory cytokines among renal transplant recipients. BMC Immunol (2015) 0.82

Translational implications of endothelial cell dysfunction in association with chronic allograft rejection. Pediatr Nephrol (2015) 0.82

Angiogenin Mediates Cell-Autonomous Translational Control under Endoplasmic Reticulum Stress and Attenuates Kidney Injury. J Am Soc Nephrol (2015) 0.81

Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance. BMC Nephrol (2015) 0.81

A Novel Extrinsic Pathway for the Unfolded Protein Response in the Kidney. J Am Soc Nephrol (2016) 0.80

Transplantation: To convert or not to convert: lessons from the CONVERT trial. Nat Rev Nephrol (2009) 0.80

Antibody-mediated rejection of the kidney after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol (2008) 0.80

Recent advances in renal interstitial fibrosis and tubular atrophy after kidney transplantation. Fibrogenesis Tissue Repair (2014) 0.80

Renal Biopsy in Type 2 Diabetic Patients. J Clin Med (2015) 0.80

Late kidney dysfunction in a kidney transplant recipient. Clin J Am Soc Nephrol (2013) 0.80

Sarcoidosis in native and transplanted kidneys: incidence, pathologic findings, and clinical course. PLoS One (2014) 0.80

The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. Transplantation (2016) 0.79

Articles by these authors

Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 25.41

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol (2000) 7.94

Methods to increase response rates to postal questionnaires. Cochrane Database Syst Rev (2007) 7.13

The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int (2007) 6.99

Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89

Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ (1998) 6.80

Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature (1990) 6.71

The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol (1996) 6.62

A common precursor for hematopoietic and endothelial cells. Development (1998) 6.58

Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study. Health Technol Assess (2007) 6.55

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Liver transplantation (1). N Engl J Med (1989) 4.53

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Relationship between nonphenacetin combined analgesics and nephropathy: a review. Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy. Kidney Int (2000) 3.86

Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest (1996) 3.73

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med (1981) 3.63

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Simple, but not branched, plasmodesmata allow the nonspecific trafficking of proteins in developing tobacco leaves. Cell (1999) 3.56

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Corticosteroids in acute traumatic brain injury: systematic review of randomised controlled trials. BMJ (1997) 3.51

Size and quality of randomised controlled trials in head injury: review of published studies. BMJ (2000) 3.51

Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant (2009) 3.43

Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43

Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res (1999) 3.41

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Should journals publish systematic reviews that find no evidence to guide practice? Examples from injury research. BMJ (2000) 3.35

Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant (2006) 3.34

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Strategies to improve recruitment to research studies. Cochrane Database Syst Rev (2007) 3.30

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation (1995) 3.18

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16

Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13

Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11

Determinants of car travel on daily journeys to school: cross sectional survey of primary school children. BMJ (1998) 3.11

International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int (1993) 3.11

Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol (2002) 3.05